REGN
Regeneron Pharmaceuticals Inc (REGN) Sec Form 8K
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Sec Form 8K
Regeneron Pharmaceuticals Inc (REGN) Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
Regeneron Pharmaceuticals Inc (REGN) TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
Regeneron Pharmaceuticals Inc (REGN) EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
Regeneron Pharmaceuticals Inc (REGN) Q1 2026 Earnings Call
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q1 2026 Earnings Conference
Regeneron Pharmaceuticals Inc (REGN) Q1 2026 Earnings Announcement
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q1 2026 Earnings Announcement
Regeneron Pharmaceuticals Inc (REGN) Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
Regeneron Pharmaceuticals Inc (REGN) Q1 2025 Earnings Call
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) Q1 2025 Earnings Conference
Regeneron Pharmaceuticals Inc (REGN) Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release
Regeneron Pharmaceuticals Inc (REGN) Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) FY 2026 Other Release